Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Antengene Starts Dose Expansion in Trial of Claudin 18.2 ADC

publication date: Mar 20, 2024

Shanghai Antengene has started the dose expansion portion of a China/Australia Phase II trial of ATG-022, a Claudin 18.2 antibody-drug conjugate. The trial, which is already underway, enrolled patients who have advanced or metastatic solid tumors, some of whom have experienced partial or complete responses. The study’s primary goal is to evaluate the safety and tolerability of ATG-022 and to determine the maximum tolerated dose (MTD) and recommended Phase II dose (RP2D) of ATG-022 as a monotherapy. The US FDA has granted two Orphan Drug Designations for ATG-022, one for gastric cancer and the another for pancreatic cancer. More details....

Stock Symbols: (HK: 6996)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital